Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Neuroendocrine × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 210 Carcinoma, Non-Small-Cell Lung 185 Prostatic Neoplasms 126 Lung Neoplasms 89 Stomach Neoplasms 77 Squamous Cell Carcinoma of Head and Neck 53 Head and Neck Neoplasms 50 Neoplasms 36 Esophageal Neoplasms 34 Neoplasm Metastasis 33 Ovarian Neoplasms 26 Pancreatic Neoplasms 25 Sarcoma 18 Urinary Bladder Neoplasms 17 Adenocarcinoma of Lung 17 Triple Negative Breast Neoplasms 16 Carcinoma, Squamous Cell 16 Nasopharyngeal Carcinoma 14 Adenocarcinoma Of Esophagus 13 Adenocarcinoma 13 Recurrence 11 Carcinoma, Ovarian Epithelial 11 Carcinoma, Transitional Cell 10 Inflammatory Breast Neoplasms 8 Esophageal Squamous Cell Carcinoma 8 Breast Neoplasms, Male 8 Nasopharyngeal Neoplasms 7 Leiomyosarcoma 7 Uterine Cervical Neoplasms 6 Salivary Gland Neoplasms 6

Interventions

Everolimus 9 Cisplatin 7 Temozolomide 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 Nivolumab 4 Etoposide 4 Carboplatin 4 Capecitabine 4 Irinotecan 3 sintilimab 2 pembrolizumab 2 dostarlimab 2 cabozantinib 2 azaspirane 2 avelumab 2 atezolizumab 2 Paclitaxel 2 Ipilimumab 2 Immunoglobulin G 2 IFL protocol 2 Fluorouracil 2 Fluorodeoxyglucose F18 2 Disulfides 2 zimberelimab 1 surufatinib 1 selinexor 1 pertuzumab 1 pasireotide 1 niraparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03837977 2024-12-30

NET02

The Christie NHS Foundation Trust

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡